Market Risers: AstraZeneca, BP, Caledonia Mining Corporation

Broker Ratings

The stock price for AstraZeneca with company EPIC: LON:AZN has stepped up 1.22% or 91.57 points throughout the session so far. Market buyers have remained positive while the stock has been in play. The periods high figure was 7646.76 while the low for the session was 7543. The total volume of shares traded by this point was 549,400 with the daily average number around 2,952,061. The 52 week high for the shares is 10120 about 2590 points in difference on the previous days close and a 52 week low being 6736 is a variance of 794 points. AstraZeneca now has a 20 SMA of 7516.08 and now its 50 day moving average now at 7316.47. The current market capitalisation is £99,893.01m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Tuesday, April 27, 2021 at 12:20:25 PM GMT with the stock price trading at 7621.57 GBX.

The share price for BP with company EPIC: LON:BP has risen 1.37% or 4.05 points throughout today’s trading session so far. Traders have so far held a positive outlook throughout the session. The periods high figure was 307.45 dipping to 296. The total volume of shares traded by this point was 20,429,440 with the daily average traded share volume around 51,478,434. The 52 week high for the shares is 508.7 around 212.15 points difference from the previous days close and the 52 week low at 188.52 which is a difference of 108.03 points. BP now has a 20 simple moving average of 302.91 and now its 50 day SMA of 304.71. The market capitalisation is now £61,069.15m at the time of this report. The share price is in Great British pence. Mcap is measured in GBP. This article was written with the last trade for BP being recorded at Tuesday, April 27, 2021 at 12:20:36 PM GMT with the stock price trading at 300.6 GBX.

The trading price for Caledonia Mining Corporation found using EPIC: LON:CMCL has moved up 4.55% or 50 points throughout today’s trading session so far. Market buyers are a positive bunch while the stock has been in play. The periods high has reached 1150 meanwhile the session low reached 1050. The volume total for shares traded up to this point was 566 with the average number of shares traded daily being 5,327. The 52 week high price for the shares is 1900 amounting to 800 points difference from the previous days close and the 52 week low at 950 a difference of some 150 points. Caledonia Mining Corporation now has a 20 SMA at 1134.19 and also a 50 day simple moving average now at 1141.77. Market capitalisation for the company is £170.39m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Caledonia Mining Corporation being recorded at Tuesday, April 27, 2021 at 9:59:02 AM GMT with the stock price trading at 1150 GBX.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

AstraZeneca’s Etcamah approved in US for ESR1-mutated advanced breast cancer

The FDA has approved Etcamah (camizestrant) with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer after detection of an emerging ESR1 mutation, based on Phase III SERENA-6 results showing a 56% reduction in the risk of disease progression or death.

BP appoints Ian Tyler as Chair

Ian Tyler has been appointed Chair of bp with immediate effect, after serving as Interim Chair since May 2026. Dame Amanda Blanc will step down from the board once a successor is appointed as Senior Independent Director.

AstraZeneca’s Tezspire meets key endpoints in Phase III EoE trial

AstraZeneca has reported positive Phase III CROSSING trial results for Tezspire in eosinophilic oesophagitis, with benefits sustained to week 52.

AstraZeneca strengthens funding position with €2.55 billion Eurobond issue

AstraZeneca has priced four tranches of Eurobonds totalling €2.55 billion, with closing expected on 1 September 2026.

AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination

Astrazeneca Plc has reported positive SAFFRON Phase III results for Tagrisso and Orpathys, showing improved progression-free and overall survival.

BP posts $5.7bn underlying profit and raises dividend in second quarter

BP has reported higher second-quarter underlying replacement cost profit and operating cash flow, alongside a reduction in net debt.

Search